NCT03951753View on ClinicalTrials.gov

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Semaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (2)

41460

Profil Institut für Stoffwechselforschung, Neuss

55116

Profil Mainz GmbH & Co. KG, Mainz

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03951753 - A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter